On-demand tickets

Our 2021 Masterclasses has been broken down into individual on-demand lectures which are available for mix-and-match purchase. This ensures we are giving you access to the most relevant and affordable content. Lectures are £20 each.

  • Exploring Value: Novel Elements for Breakthrough Treatment.

    What is Value?

    Martina Garau
    Director | OHE

    Associated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.

    Lecture duration: 05:47

    • Exploring the expanded and actionable definition of value
    • Discussing how broader value elements resonate with decision makers
    • Understanding the practical and policy challenges faced by adopting broader value elements
    Buy this lecture | FREE
  • Exploring Value: Novel Elements for Breakthrough Treatment.

    What are the novel and established sources of value?

    Professor Adrian Towse
    Director Emeritus and Senior Research Fellow | OHE

    Associated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.

    Lecture duration: 17:19

    • Exploring a brief history of established sources of value
    • Analysing novel value elements and what they entail
    • Discussing which value elements should be considered
    Buy this lecture | £20
  • Exploring Value: Novel Elements for Breakthrough Treatment.

    Methods and practice to consider broader value elements in decision making

    Martina Garau
    Director | OHE

    Associated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.

    Lecture duration: 17:01

    • Exploring the need for an aggregation method for multiple value elements
    • Outlining the implications of cost effectiveness benchmarks
    • Discussing the continuum of decision making approaches from deliberative to quantitative with real-world examples
    Buy this lecture | £20
  • Patient Outcomes: Measuring What Matters to Patients.

    What do health systems aim to maximise?

    Patricia Cubi-Molla
    Senior Principal Economist | OHE

    Associated Masterclass: Patient Outcomes: Measuring What Matters to Patients.

    Lecture duration: 18:54

    • Public sector spending and research allocation
    • Healthcare sector spending through measuring patient preference
    • Health technologies spending through measuring outcomes
    Buy this lecture | £20
  • Patient Outcomes: Measuring What Matters to Patients.

    Going beyond patients’ health-related quality of life – wellbeing and carers health-related quality of life

    Dr David Mott
    Principal Economist | OHE

    Associated Masterclass: Patient Outcomes: Measuring What Matters to Patients.

    Lecture duration: 19:35

    • Outlining when and how the quality of life of carers should be measured
    • Discussing the potential impact of carer quality of life measurement on HTA
    • Exploring broader outcome measurements and their scope for use in HTA
    Buy this lecture | £20
  • Patient Outcomes: Measuring What Matters to Patients.

    Alternative approaches to measure patient outcomes (within the QALY framework)

    Dr Chris Sampson
    Principal Economist | OHE

    Associated Masterclass: Patient Outcomes: Measuring What Matters to Patients.

    Lecture duration: 19:52

    • Exploring alternative generic measures for patient outcomes
    • Outlining condition-specific measures and their potential advantages
    • Introducing bolt-ons methods
    Buy this lecture | £20
  • The Patient Voice: Capturing Patient Preferences in Decision-Making.

    The ‘patient voice’ in health technology assessment

    Dr Chris Skedgel
    Director | OHE

    Associated Masterclass: The Patient Voice: Capturing Patient Preferences in Decision-Making.

    Lecture duration: 13:40

    • Explaining patient preferences in HTA
    • Discussing empirical evidence around the role of patient preferences in HTA
    • Outlining the future of the patient voice in HTA
    Buy this lecture | £20
  • The Patient Voice: Capturing Patient Preferences in Decision-Making.

    How are patient preferences elicited?

    Dr David Mott
    Principal Economist | OHE

    Associated Masterclass: The Patient Voice: Capturing Patient Preferences in Decision-Making.

    Lecture duration: 19:57

    • Methodologies used to elicit quantitative patient preference data
    • The typical stages of a quantitative patient preference study
    • The type of insights that can be obtained from quantitative patient preference data
    Buy this lecture | £20
  • Research and Development (R&D) for OMPs

    Professor Adrian Towse
    Director Emeritus and Senior Research Fellow | OHE

    Associated Masterclass: Innovation for Small Populations: What Should We Pay for?

    Lecture duration: 20:16

    • Is Market Exclusivity (ME) needed to incentivise the Research & Development (R&D) of Orphan Medical Products (OMPs)?
    • Are R&D costs for individual OMPs lower than those for medicines for more common conditions?
    • What is a fair price for OMPs?
    Buy this lecture | £20
  • HTA for Orphan Medicinal Products (OMPs)

    Dr Chris Skedgel
    Director | OHE

    Associated Masterclass: Innovation for Small Populations: What Should We Pay for?

    Lecture duration: 19:32

    • Are health conditions been salami-sliced to drive exceptionalism?
    • Can evidence in support of Health Technology Assessment (HTA) submissions for OMPs meet the same standards as medicines for more common conditions?
    • What is society willingness to prioritise treatments for rare conditions?
    Buy this lecture | £20
  • Adaptive Pathways: Generating Evidence of Value.

    Bridging the gap between regulatory and reimbursement

    Professor Lotte Steuten
    Vice President | OHE

    Associated Masterclass: Adaptive Pathways: Generating Evidence of Value.

    Lecture duration: 22:28

    • Elements driving uncertainty at an early stage of a treatment introduction
    • Using surrogate endpoints in clinical trials
    • How different types of uncertainty can be addressed, including conditional reimbursement schemes
    Buy this lecture | £20
  • Adaptive Pathways: Generating Evidence of Value.

    Are Adaptive Pathways always the answer?

    Professor Adrian Towse
    Director Emeritus and Senior Research Fellow | OHE

    Associated Masterclass: Adaptive Pathways: Generating Evidence of Value.

    Lecture duration: 20:55

    • Implications of accelerated approval for payer uncertainty
    • Application of the value of information approach to inform optimal use of risk sharing schemes
    • When companies should actively seek an AP
    Buy this lecture | £20
  • Adaptive Pathways: Generating Evidence of Value.

    Adaptive Pathways: insights from the experience in Europe and the UK.

    Isobel Firth
    Senior economist | OHE

    Associated Masterclass: Adaptive Pathways: Generating Evidence of Value.

    Lecture duration: 17:36

    • Accelerated Pathways (AP) introduced by the EMA and MHRA
    • What APs mean to development and access to medicines
    • Examples of early access in Europe
    Buy this lecture | £20